Comparative pharmacokinetics of LMWHs

Seminars in Thrombosis and Hemostasis

Volumn 26, Issue 3 SUPPL. 1, 2000, Pages 31-38

  Samama, M M ^a   Gerotziafas, G T ^a  

^a HÔTEL DIEU   (France)

Author keywords

Anti Xa and aIIa activity; Low molecular weight heparins; Pharmacokinetic and pharmacodynamic characteristics and differences

Indexed keywords

ARDEPARIN; BLOOD CLOTTING FACTOR 10A; DALTEPARIN; ENOXAPARIN; HEPARIN DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PARNAPARIN; PROTHROMBIN A; REVIPARIN; TINZAPARIN;

ANTICOAGULATION; AREA UNDER THE CURVE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG METABOLISM; DRUG SAFETY; HUMAN; HUMAN EXPERIMENT; KIDNEY FAILURE; MEAN RESIDENCE TIME; MOLECULAR WEIGHT; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PEDIATRICS; PHARMACODYNAMICS; PREGNANCY; PRIORITY JOURNAL; PROPHYLAXIS; THROMBOEMBOLISM;

AGE FACTORS; CLINICAL TRIALS; FACTOR XA; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; PREGNANCY; THROMBOSIS;

EID: 0033817335     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (40)

1. Low-molecular-weight heparins
2. Low-molecular-weight heparins
3. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group
4. Mode of action of unfractionated and low-molecular-weight heparins on the generation of thrombin in plasma
5. The mode of action of hepatin in plasma
6. Comparative effects of synthetic pentasaccharide, low-molecular-weight heparin unfractionated heparin and recombinant hirudin on the generation of factor VIIa and prothrombin activation after coagulation of human plasma
7. Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor
8. Specific anti-Xa activity of LMWH (Kabi 2165, CY 216, PK 10169) against the first international standard of LMWH: A collaborative study
9. The antithrombotic activity and PK of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg
10. Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers
11. A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers
12. Tinzaparin. A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders
13. A cross-over comparison of the anti-clotting effects of three low molecular weight heparins and glycosaminoglycuronan
14. Comparison of the pharmacokinetic profiles of three low molecular mass heparins - Dalteparin, enoxaparin and nadroparin - Administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism)
15. Pharmacokinetics of a low molecular weight heparin, logiparin, after intravenous and subcutaneous administration to healthy volunteers
16. Pharmacokinetics of a low molecular weight heparin [Fragmin] in young and elderly subjects
17. Low-molecular-weight heparins: An overview of their pharmacodynamics, pharmacokinetics and metabolism in humans
18. Biochemical and pharmacologic characteristics of Reviparin, a low-molecular-mass heparin
19. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery
20. Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. FRAXODI group
21. Prevention of deep vein thrombosis after hip replacement. Comparison between two low-molecular-weight heparins, tinzaparin and enoxaparin
22. Low molecular weight heparin (KAB1 2165. Fragmin): Pharmacokinetics after intravenous and subcutaneous administration in human volunteers
23. Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins
24. Pharmacokinetics of heparin and low molecular weight heparin
25. Pharmacokinetics and biodistribution of technetium 99m labelled standard heparin and a low molecular weight heparin (enoxaparin) after intravenous injection in normal volunteers
26. Delayed elimination of enoxaparin in patients with chronic renal insufficiency
27. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low-molecular-weight heparin (nadroparin)
28. Absolute and comparative subcutaneous bioavailability of ardeparin sodium, a low-molecular-weight heparin
29. Placental transport of low-molecular-weight heparin in the pregnant sheep
30. Tinzaparin administered once daily in elderly (175 anti-Xa 1U/kg) : A pharmacokinetic study over 10 days
31. A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy
32. Thromboprophylaxis with low-molecular-weight heparin (dalteparin) in pregnancy
33. Thromboprophylaxis with low-molecular-mass heparin, 'Fragmin' (dalteparin), during pregnancy - A longitudinal safety study
34. Lack of anti-factor Xa activity in umbilical cord vein samples after subcutaneous administration of heparin or low molecular mass heparin in pregnant women
35. Heparin therapy in pediatric patients
36. Antithrombotic therapy in children
37. Low-molecular-weight heparin in pediatric patients with thrombotic disease: A dose finding study
38. A cross-over dose-finding study investigating a low molecular weight heparin (Fragmin®) in six children on chronic-hemodialysis
39. Prevention of hepatic artery thrombosis in pediatric liver transplantation
40. Renal transplantation in children under five years of age. Experience at the Hopital des Enfants-Malades